Repositioning of 8565 Existing Drugs for COVID-19

Kaifu Gao; Duc Duy Nguyen; Jiahui Chen; Rui Wang; Guo Wei Wei

doi:10.1021/acs.jpclett.0c01579

Repositioning of 8565 Existing Drugs for COVID-19

Kaifu Gao, Duc Duy Nguyen, Jiahui Chen, Rui Wang, Guo Wei Wei

Producción científica: Review article › revisión exhaustiva

80 Citas (Scopus)

Resumen

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 7.1 million people and led to over 0.4 million deaths. Currently, there is no specific anti-SARS-CoV-2 medication. New drug discovery typically takes more than 10 years. Drug repositioning becomes one of the most feasible approaches for combating COVID-19. This work curates the largest available experimental data set for SARS-CoV-2 or SARS-CoV 3CL (main) protease inhibitors. On the basis of this data set, we develop validated machine learning models with relatively low root-mean-square error to screen 1553 FDA-approved drugs as well as another 7012 investigational or off-market drugs in DrugBank. We found that many existing drugs might be potentially potent to SARS-CoV-2. The druggability of many potent SARS-CoV-2 3CL protease inhibitors is analyzed. This work offers a foundation for further experimental studies of COVID-19 drug repositioning.

Idioma original	English
Páginas (desde-hasta)	5373-5382
Número de páginas	10
Publicación	Journal of Physical Chemistry Letters
Volumen	11
N.º	13
DOI	https://doi.org/10.1021/acs.jpclett.0c01579
Estado	Published - jul 2 2020

Nota bibliográfica

Publisher Copyright:
Copyright © 2020 American Chemical Society.

Financiación

This work was supported in part by NIH Grant GM126189; NSF Grants DMS-1721024, DMS-1761320, and IIS1900473; Michigan Economic Development Corporation; Bristol-Myers Squibb; and Pfizer. The authors thank The IBM TJ Watson Research Center, The COVID-19 High Performance Computing Consortium, NVIDIA, and MSU HPCC for computational assistance supporting this work.

Financiadores	Número del financiador
National Science Foundation Arctic Social Science Program	IIS1900473, DMS-1721024, DMS-1761320
National Institutes of Health (NIH)
National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical Sciences	R01GM126189
Bristol-Myers Squibb
Pfizer
Michigan Economic Development Corporation

ASJC Scopus subject areas

General Materials Science
Physical and Theoretical Chemistry

Acceder al documento

10.1021/acs.jpclett.0c01579

Otros archivos y enlaces

Citar esto

@article{c415e7bb161848399fba67ca8ed789cf,

title = "Repositioning of 8565 Existing Drugs for COVID-19",

abstract = "The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 7.1 million people and led to over 0.4 million deaths. Currently, there is no specific anti-SARS-CoV-2 medication. New drug discovery typically takes more than 10 years. Drug repositioning becomes one of the most feasible approaches for combating COVID-19. This work curates the largest available experimental data set for SARS-CoV-2 or SARS-CoV 3CL (main) protease inhibitors. On the basis of this data set, we develop validated machine learning models with relatively low root-mean-square error to screen 1553 FDA-approved drugs as well as another 7012 investigational or off-market drugs in DrugBank. We found that many existing drugs might be potentially potent to SARS-CoV-2. The druggability of many potent SARS-CoV-2 3CL protease inhibitors is analyzed. This work offers a foundation for further experimental studies of COVID-19 drug repositioning.",

author = "Kaifu Gao and Nguyen, \{Duc Duy\} and Jiahui Chen and Rui Wang and Wei, \{Guo Wei\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2020 American Chemical Society.",

year = "2020",

month = jul,

day = "2",

doi = "10.1021/acs.jpclett.0c01579",

language = "English",

volume = "11",

pages = "5373--5382",

number = "13",

}

TY - JOUR

T1 - Repositioning of 8565 Existing Drugs for COVID-19

AU - Gao, Kaifu

AU - Nguyen, Duc Duy

AU - Chen, Jiahui

AU - Wang, Rui

AU - Wei, Guo Wei

PY - 2020/7/2

Y1 - 2020/7/2

N2 - The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 7.1 million people and led to over 0.4 million deaths. Currently, there is no specific anti-SARS-CoV-2 medication. New drug discovery typically takes more than 10 years. Drug repositioning becomes one of the most feasible approaches for combating COVID-19. This work curates the largest available experimental data set for SARS-CoV-2 or SARS-CoV 3CL (main) protease inhibitors. On the basis of this data set, we develop validated machine learning models with relatively low root-mean-square error to screen 1553 FDA-approved drugs as well as another 7012 investigational or off-market drugs in DrugBank. We found that many existing drugs might be potentially potent to SARS-CoV-2. The druggability of many potent SARS-CoV-2 3CL protease inhibitors is analyzed. This work offers a foundation for further experimental studies of COVID-19 drug repositioning.

AB - The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 7.1 million people and led to over 0.4 million deaths. Currently, there is no specific anti-SARS-CoV-2 medication. New drug discovery typically takes more than 10 years. Drug repositioning becomes one of the most feasible approaches for combating COVID-19. This work curates the largest available experimental data set for SARS-CoV-2 or SARS-CoV 3CL (main) protease inhibitors. On the basis of this data set, we develop validated machine learning models with relatively low root-mean-square error to screen 1553 FDA-approved drugs as well as another 7012 investigational or off-market drugs in DrugBank. We found that many existing drugs might be potentially potent to SARS-CoV-2. The druggability of many potent SARS-CoV-2 3CL protease inhibitors is analyzed. This work offers a foundation for further experimental studies of COVID-19 drug repositioning.

UR - https://www.scopus.com/pages/publications/85087530327

UR - https://www.scopus.com/inward/citedby.url?scp=85087530327&partnerID=8YFLogxK

U2 - 10.1021/acs.jpclett.0c01579

DO - 10.1021/acs.jpclett.0c01579

M3 - Review article

C2 - 32543196

AN - SCOPUS:85087530327

VL - 11

SP - 5373

EP - 5382

JO - Journal of Physical Chemistry Letters

JF - Journal of Physical Chemistry Letters

IS - 13

ER -

Repositioning of 8565 Existing Drugs for COVID-19

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto